For condition: Psoriasis
Research Trial for Moderate-to-Severe Plaque Psoriasis (154 Weeks)
Study Summary
Who Can Participate?
Adults (≥ 18 years of age) who have plaque psoriasis, may be eligible to participate.
Inclusion Criteria:
- Body Mass Index (BMI) ≥ 18.5 kg/m2
- Diagnosis of stable chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months
- Moderate-to-severe disease, with a Body Surface Area (BSA) ≥ 10% (i.e. 10 handprints)
- Candidate for systemic therapy or phototherapy for psoriasis treatment
Participant Info:
- No cost to participate or receive study medication
- Regular visits with study doctors who are familiar with treating plaque psoriasis
- Will receive investigational injected medication (active study drug) or placebo
- Reimbursement for study-related expenses may be provided
How Long Will The Study Last?
Participation will last about 154 weeks and involve about 23 visits to the study research site (plus 2 phone visits).
After you have completed the study, you may have the opportunity to continue receiving ORKA-001 through another study. The study team will discuss this with you in further detail.
For more information about this trial, please visit ClinicalTrials.gov
